Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| CALGB-30506 | CALGB | A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-30607 | CALGB | Randomized; Phase III; Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511; IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced; Stage IIIB/IV Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-30610 | CALGB | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-30801 | CALGB | A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-40101 | CALGB | Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-40302 | CALGB | Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-40502 | CALGB | A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer<br> | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-40503 | CALGB | Endocrine Therapy with or without ANTI-VEGF Therapy: A Randomized; Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-40601 | CALGB | Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-49808 | CALGB | A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002** | Adult CIRB - Late Phase Emphasis | Completed |